Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accounts Payables: 2023-2025

Historic Accounts Payables for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $3.1 million.

  • Compass Therapeutics' Accounts Payables rose 222.40% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 222.40%. This contributed to the annual value of $2.2 million for FY2024, which is 45.01% down from last year.
  • Per Compass Therapeutics' latest filing, its Accounts Payables stood at $3.1 million for Q3 2025, which was up 19.27% from $2.6 million recorded in Q2 2025.
  • Compass Therapeutics' Accounts Payables' 5-year high stood at $4.1 million during Q4 2023, with a 5-year trough of $724,000 in Q2 2023.
  • Moreover, its 3-year median value for Accounts Payables was $1.6 million (2025), whereas its average is $1.9 million.
  • As far as peak fluctuations go, Compass Therapeutics' Accounts Payables plummeted by 58.37% in 2024, and later skyrocketed by 222.40% in 2025.
  • Compass Therapeutics' Accounts Payables (Quarterly) stood at $4.1 million in 2023, then tumbled by 45.01% to $2.2 million in 2024, then soared by 222.40% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $2.6 million for Q2 2025, and $1.6 million during Q1 2025.